Alivus Life Sciences Limited (BOM:543322)
India · Delayed Price · Currency is INR 1,001.25
-29.05 (-2.82%)
At close: Aug 1, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2021 |
Net Income | - | 4,856 | 4,709 | 4,670 | 4,187 | 3,516 | Upgrade |
Depreciation & Amortization | - | 606.09 | 497.78 | 406.48 | 369.2 | 322.9 | Upgrade |
Other Amortization | - | - | 36.74 | 14.46 | 9.57 | 11.04 | Upgrade |
Loss (Gain) From Sale of Assets | - | 18.21 | 10.11 | 5.58 | 7.43 | 5.84 | Upgrade |
Stock-Based Compensation | - | - | 43.75 | 31.85 | 34.98 | - | Upgrade |
Provision & Write-off of Bad Debts | - | 4.81 | 31.66 | 3.71 | 48.19 | - | Upgrade |
Other Operating Activities | - | 233.64 | 147.03 | 64.97 | 320.84 | 1,101 | Upgrade |
Change in Accounts Receivable | - | -2,048 | 378.6 | -1,336 | -592.15 | 81.01 | Upgrade |
Change in Inventory | - | -388.55 | -826.26 | -972.27 | -28.23 | -1,006 | Upgrade |
Change in Accounts Payable | - | 187.46 | -341.21 | 907.79 | 737.49 | 340.89 | Upgrade |
Change in Other Net Operating Assets | - | 445.2 | -551.93 | -735.63 | 881.29 | -491.21 | Upgrade |
Operating Cash Flow | - | 3,915 | 4,135 | 3,060 | 5,976 | 3,881 | Upgrade |
Operating Cash Flow Growth | - | -5.32% | 35.13% | -48.79% | 53.97% | 99.02% | Upgrade |
Capital Expenditures | - | -1,662 | -1,290 | -1,628 | -1,322 | -679.93 | Upgrade |
Sale of Property, Plant & Equipment | - | 6.29 | 4.65 | 1.74 | 4.69 | 16.34 | Upgrade |
Investment in Securities | - | -4,701 | - | 1.11 | 28.05 | -28.05 | Upgrade |
Other Investing Activities | - | 200.13 | 120.21 | 157.66 | 66.7 | 4.3 | Upgrade |
Investing Cash Flow | - | -6,156 | -1,165 | -1,467 | -1,222 | -687.34 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -9,329 | -2,138 | Upgrade |
Long-Term Debt Repaid | - | -44.86 | -22.09 | -11.28 | -13.65 | - | Upgrade |
Total Debt Repaid | - | -44.86 | -22.09 | -11.28 | -9,342 | -2,138 | Upgrade |
Net Debt Issued (Repaid) | - | -44.86 | -22.09 | -11.28 | -9,342 | -2,138 | Upgrade |
Issuance of Common Stock | - | 6.69 | - | - | 10,119 | - | Upgrade |
Common Dividends Paid | - | - | -2,757 | -3,859 | -1,287 | - | Upgrade |
Other Financing Activities | - | -24.14 | -15.46 | -5.47 | -277.64 | - | Upgrade |
Financing Cash Flow | - | -62.31 | -2,794 | -3,876 | -787.96 | -2,138 | Upgrade |
Net Cash Flow | - | -2,304 | 175.91 | -2,283 | 3,966 | 1,056 | Upgrade |
Free Cash Flow | - | 2,253 | 2,845 | 1,432 | 4,654 | 3,201 | Upgrade |
Free Cash Flow Growth | - | -20.81% | 98.69% | -69.23% | 45.39% | 122.55% | Upgrade |
Free Cash Flow Margin | - | 9.44% | 12.46% | 6.63% | 21.92% | 16.98% | Upgrade |
Free Cash Flow Per Share | - | 18.34 | 23.19 | 11.69 | 39.60 | 29.69 | Upgrade |
Cash Interest Paid | - | 22.97 | 15.46 | 5.47 | 277.64 | - | Upgrade |
Cash Income Tax Paid | - | 1,630 | 1,630 | 1,536 | 1,382 | 1,086 | Upgrade |
Levered Free Cash Flow | - | 1,381 | 2,108 | 553.75 | 3,756 | 1,715 | Upgrade |
Unlevered Free Cash Flow | - | 1,396 | 2,117 | 557.17 | 3,931 | 2,262 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.